Outcomes in COVID-19 brensocatib studies

0 0.5 1 1.5+ All studies -41% 1 404 Improvement, Studies, Patients Relative Risk Mortality -41% 1 404 RCTs -41% 1 404 Late -41% 1 404 Brensocatib for COVID-19 c19early.org November 2025 Favorsbrensocatib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] death 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] death 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] death 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] death 29/190 23/214 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk All studies -41% 1.41 [1.06-1.88] 29/190 23/214 41% higher risk 1 brensocatib COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Effect extraction pre-specified(most serious outcome) Favors brensocatib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOP-COVID19 Keir (DB RCT) -41% 1.41 [1.06-1.88] death 29/190 23/214 Improvement, RR [CI] Treatment Control STOP-COVID19 Keir (DB RCT) -39% 1.39 [1.09-1.75] 7-point status 190 (n) 214 (n) Brensocatib COVID-19 outcomes c19early.org November 2025 Favors brensocatib Favors control